Mark Cuban’s Provocative AI Advice: Ask Where Your Company Is Getting Ripped Off

What if one of the most valuable applications of artificial intelligence has little to do with generating content, replacing employees, or accelerating routine tasks? What if its greatest immediate contribution to business leadership is helping executives discover how much money their organizations may be spending unnecessarily?

That was the provocative question underlying remarks by entrepreneur and investor Mark Cuban during a November 5, 2026, appearance at Becker’s CEO+CFO Roundtable. Speaking with Becker’s Healthcare founder Scott Becker, Cuban challenged hospital executives to examine the complicated financial arrangements governing employee healthcare benefits, insurance coverage, and prescription drug purchases. His recommendation was unusually direct: analyze those contracts with artificial intelligence and ask, “Where are they ripping me off?” The remark, reported by Becker’s Healthcare, was more than a colorful criticism of healthcare pricing. It raised a consequential question about modern corporate management: How many organizations have become accustomed to financial arrangements they no longer fully understand?

The $150,000 Difference That Got Mark Cuban’s Attention

Cuban offered a revealing example from his experience with the Dallas Mavericks, the NBA franchise he formerly controlled. After reviewing the team’s purchases of generic prescription medications over an 18-month period, he discovered what he described as an extraordinary discrepancy. According to Cuban, the organization had spent approximately $169,000 on medications that would have cost approximately $19,000 through Mark Cuban Cost Plus Drug Company, the pharmaceutical venture he co-founded to challenge conventional drug pricing. The difference was approximately $150,000—nearly 89% of the original expenditure. Those figures represent Cuban’s account of the comparison, not an independently audited finding. Nor do they establish that every organization could achieve comparable savings. Differences in purchasing arrangements, product availability, contractual obligations, and benefits administration can materially affect actual costs.

Nevertheless, the example exposes a problem that extends beyond pharmaceuticals. Organizations frequently rely on established vendors, brokers, consultants, and intermediaries to manage complicated transactions. These relationships may provide genuine expertise and operational value, but they can also create distance between the people authorizing expenditures and the underlying economics of those purchases. Over time, complexity can become a substitute for scrutiny. Contracts are renewed, invoices are approved, and purchasing practices continue because they are familiar rather than because their value has been independently established. Cuban’s experience suggests that financial discipline requires more than negotiating favorable prices at the outset of a relationship. It also demands periodically questioning whether the structure of that relationship continues to serve the organization’s interests.

Artificial Intelligence as a Tool for Challenging the Status Quo

The significance of Cuban’s recommendation lies in artificial intelligence’s growing capacity to examine documents and financial information that would otherwise require substantial human effort to review. Healthcare agreements can extend hundreds or even thousands of pages, containing intricate provisions governing rebates, administrative fees, drug classifications, reimbursement arrangements, and audit rights. Cuban argued that these contractual complexities can obscure opportunities for employers to negotiate more favorable terms. AI-assisted analysis may help identify unusual provisions, compare agreements, flag inconsistent pricing arrangements, and formulate questions for legal, financial, and procurement professionals. It can also make information more accessible to executives who previously depended almost entirely on intermediaries to interpret it.

Cuban explored similar themes during an October 2026 Reuters Newsmaker discussion with Reuters U.S. Health and Pharma Editor Caroline Humer. Their conversation addressed artificial intelligence in medicine, pharmaceutical affordability, healthcare investment, and the need for greater competition and transparency.  He developed the argument further in an October 28 conversation with venture capital firm Andreessen Horowitz, published on its a16z channel. Discussing the future of healthcare with Julie Yoo and Erik Torenberg, Cuban emphasized that technology alone cannot correct distorted financial incentives. Greater transparency must be accompanied by a willingness to challenge the arrangements that perpetuate unnecessary costs.

His approach also exposes an important distinction between identifying a potential problem and establishing that wrongdoing has occurred. An AI system may flag an unfavorable provision or an unexpected pricing difference, but it cannot independently determine whether a charge is improper, whether a contractual term is commercially reasonable, or whether a proposed alternative is financially superior.

Those conclusions require qualified human judgment, reliable underlying data, and careful consideration of contractual context. Confidentiality is equally important. Organizations examining sensitive agreements should use approved, secure enterprise AI environments with appropriate access controls and data protections, rather than uploading proprietary contracts or employee information into unapproved public systems. The technology’s greatest value may therefore be neither automatic decision-making nor effortless cost reduction. It may be its ability to make complicated arrangements more intelligible, allowing executives to ask better questions and demand more accountable answers.

 

Mark Cuban on Why AI Could Turn Solo Founders Into Trillionaires | a16z | October 28, 2026

What Mark Cuban’s Approach Means for Business Leaders

Although Cuban directed his November remarks toward healthcare executives, the underlying argument applies across industries. Manufacturers manage complicated supplier agreements. Retailers negotiate distribution and logistics contracts. Technology companies accumulate software subscriptions and cloud-service commitments. Large employers administer extensive benefits programs, while professional services organizations depend on outside vendors whose pricing structures may be difficult to compare. In each case, financial inefficiency can become embedded in ordinary operations, particularly when contractual complexity discourages independent examination.

Cuban’s challenge invites leaders to reconsider the relationship between information and accountability. An organization may possess enormous quantities of financial data yet lack the practical ability to convert that information into meaningful oversight. AI offers one potential means of narrowing that gap, but only when executives are prepared to act on what the analysis reveals. That may require renegotiating contracts, reconsidering established suppliers, examining the incentives of intermediaries, or questioning purchasing assumptions that have remained unchallenged for years. It also requires recognizing that the lowest apparent price is not always the best commercial outcome. Reliability, service quality, regulatory obligations, and long-term relationships remain legitimate considerations. The broader business lesson is an editorial extension of Cuban’s healthcare-focused remarks: Artificial intelligence may create substantial value not simply by improving existing processes, but by revealing which processes deserve to be reconsidered altogether.

For CEOs and CFOs, this represents a different conception of technological innovation. Rather than measuring AI’s contribution exclusively through productivity gains or labor savings, organizations might also evaluate its ability to improve financial visibility, strengthen procurement oversight, and expose assumptions that no longer withstand scrutiny. Cuban has built a career around questioning established business models, from internet broadcasting and professional sports to entrepreneurship and pharmaceutical pricing. His latest challenge is consistent with that philosophy: understanding the economics of an industry is often the first step toward changing them.

Book Entrepreneur and Innovation Keynote Speaker Mark Cuban

For organizations confronting technological change, competitive pressure, and increasingly complex business decisions, Mark Cuban brings an unusually practical perspective on entrepreneurship, innovation, and strategic disruption. A self-made billionaire, former longtime investor on ABC’s Shark Tank, former principal owner of the Dallas Mavericks, and co-founder of Mark Cuban Cost Plus Drug Company, Cuban has repeatedly challenged conventional assumptions about how industries operate and where opportunities for innovation emerge. His experience makes him a compelling voice for corporate leadership conferences, entrepreneurship and innovation events, technology and AI conferences, healthcare leadership meetings, business strategy forums, executive retreats, and professional association gatherings. His recent comments about artificial intelligence and healthcare pricing illustrate a larger principle that resonates across business sectors: meaningful innovation begins with the willingness to examine accepted practices, understand their economic consequences, and consider whether a better approach is possible.

To inquire about booking Mark Cuban for your next conference or corporate event, contact Speakers.com for speaking fees, availability, and additional information.

PLEASE NOTE: Speakers.com is a booking agency for paid speaking engagements and events only. We do not handle media interviews, podcast appearances, book tours, pro bono requests, or provide celebrity contact information.

Speakers Mentioned

Your Speakers

Please add any speakers you are interested in to your list. You can send this list to us to inquire about availability.

Clear All

No Speakers in List

Scroll to Top